TY - JOUR T1 - Acute respiratory distress syndrome is associated with impaired alveolar macrophage efferocytosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00829-2021 VL - 58 IS - 3 SP - 2100829 AU - Mahida, Rahul Y. AU-Scott，Aaron au -Parekh，Dhruv au -Lugg，Sebastian T. Au -Hardy，Rowan S. Au -Lavery，Gareth G. Au -Matthay，Matthay，Michael A. Au -Naidu，Babu Au -Perkins，Perkins，Gavin D. Au D. Au au au au au au au au au au au- 厚底，David R. Y1-2021/09/01 UR- http：//www.qdcxjkg.com/content/58/3/3/2100829.abstract N2-急性呼吸遇险综合征（ARDS）是肺部炎症性疾病，以败血症为主要的病因。尽管通风策略取得了进步，但中度至重度ARD的死亡率仍为40-46％[1]。ARDS与中性粒细胞流入肺泡有关。支气管肺泡灌洗液（BAL）液中的持续高的嗜中性粒细胞和低肺泡巨噬细胞（AM）数量与更大的死亡率有关[2]。尽管早期ARD的炎症性肺泡环境最初延迟了凋亡，但这些中性粒细胞最终在肺泡内发生凋亡[3]。AMS对凋亡中性粒细胞对凋亡的有效吞噬作用对于解决炎症至关重要[3]。凋亡中性粒细胞可能由于AM肿瘤病和/或不知所措的胞吐能力而在ARDS中积聚，然后经历继发性坏死，将炎症性介体释放到肺泡空间中[4]。这可能导致在ARDS中观察到的延长炎症。 No study has previously assessed AM efferocytosis in ARDS; however, monocyte-derived macrophages (MDMs) from ARDS patients do have impaired efferocytosis [5]. We investigated whether ARDS patients have impaired AM efferocytosis and increased alveolar neutrophil apoptosis.ARDS patients have decreased alveolar macrophage efferocytosis, which is associated with increased alveolar inflammation, and may contribute to worse clinical outcomes, including mortality. Upregulation of efferocytosis may offer a therapeutic strategy. https://bit.ly/2Q7REdM ER -